Conclusions Inositol supplementation may result in reduction in triglycerides , total- and LDL-cholesterol levels , but did not affect HDL-cholesterol levels  among patients with metabolic diseases .
Background Several studies have evaluated the effect of inositol supplementation on lipid profiles among population with metabolic diseases ; however , the findings are controversial .
This review of r and omized controlled trials ( RCTs ) was performed to summarize the evidence of the effects of inositol supplementation on lipid profiles among population with metabolic diseases .
Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation.
DESIGN AND PURPOSE The supplemental administration of myo-inositol , D-chiro-inositol , folic acid and manganese ( MDFM ) was tested in a prospect i ve , r and omized , double-blind , placebo controlled clinical trial , pilot study , to test the hypothesis that its supplemental administration in the second trimester of pregnancy would improve glucose and glycemic parameters and blood pressure . SUBJECTS AND METHODS Non-obese uniparous healthy pregnant women between 13th and 24th week of pregnancy were divided into two groups : group I , control group with placebo , and the group II , women in treatment with myo-inositol , D-chiro-inositol , folic acid and manganese . The main outcome measures were the comparative analysis of the parameters analyzed at time 0 , after 30 days and 60 days ; secondary outcome measure was the overall analysis of investigated parameters . RESULTS 24 women were allocated to receive MDFM and 24 the placebo . The two groups did not significantly differ for demographic , lipidic and glycemic parameter and blood pressure . After 30 days , significantly lower cholesterol ( p = 0.0001 ) , significantly lower LDL ( p = 0.0013 ) , lower TG ( p < 0.0001 ) and lower glycemia ( p = 0.0021 ) were observed all favoring group II . No significant difference was observed for HDL , diastolic and systolic blood pressure . After 60 days , significant difference was observed for cholesterol ( p = 0.0001 ) , LDL ( p = 0.0001 ) , HDL ( p = 0.0001 ) , TG ( p = 0.0001 ) , glycemia ( p = 0.0064 ) , all favoring the group treated with MDFM . No significant differences were observed for systolic ( p = 0.12 ) and diastolic blood pressure ( p = 0.42 ) . When examining for overall differences between the two groups , a significant difference was observed for examined parameters at time 0 and at time 60 ; cholesterol ( p = 0.0001 ) , LDL ( p = 0.0001 ) , HDL ( p = 0.047 ) , TG ( p = 0.0001 ) and glycemia ( p = 0.019 ) were reduced in the MDFM group . A significant reduction was also observed in group II for systolic blood pressure after 60 days of intervention ( p = 0.0092 ) , but not for diastolic blood pressure ( p = 0.29 ) . CONCLUSIONS MDFM administration after 30 days in pregnancy improved glycemic and lipidic parameters , with significant gain after 60 days , without affecting diastolic blood pressure levels
Conclusions Inositol supplementation may result in reduction in triglycerides , total- and LDL-cholesterol levels , but did not affect HDL-cholesterol levels  among patients with metabolic diseases .
Background Several studies have evaluated the effect of inositol supplementation on lipid profiles among population with metabolic diseases ; however , the findings are controversial .
This review of r and omized controlled trials ( RCTs ) was performed to summarize the evidence of the effects of inositol supplementation on lipid profiles among population with metabolic diseases .